Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Company In An Emerging Market: Generon Sees Quality And Price As Litmus Test

This article was originally published in PharmAsia News

Executive Summary

Generon in Shanghai was founded by former Hutchison MediPharma employees to target a niche market between expensive import drugs and lower quality domestic products.

You may also be interested in...



With Government Support, China Medical City Looks To Separate Itself From The Pack

NEW YORK - Perhaps the largest hurdle China Medical City faces with a U.S. audience is explaining how it differs from China's more established science and technology parks like Zhangjiang Hi Tech Park in Shanghai, Zhong-guan-cun Life Science Park in Beijing and BioBay in Suzhou

Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way

CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit

Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU

Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.

Topics

Related Companies

UsernamePublicRestriction

Register

SC084396

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel